Bimatoprost SR for Glaucoma Therapy Implanted at the Slit-Lamp in a Real-World Setting

References

• Realini T. A history of glaucoma pharmacology. Optom Vis Sci. 2011;88(1):36–38. doi:10.1097/OPX.0b013e3182058ead
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713. doi:10.1001/archopht.120.6.701
   PubMed Web of Science ®Google Scholar
• Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I. Results of the European glaucoma prevention study. Ophthalmology. 2005;112(3):366–375. doi:10.1016/j.ophtha.2005.06.020
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–1279. doi:10.1001/archopht.120.10.1268
   PubMed Web of Science ®Google Scholar
• Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11):1943–1953. doi:10.1016/S0161-6420(01)00873-9
   PubMed Web of Science ®Google Scholar
• Laser Trial Research Group G, Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and Glaucoma Laser Trial Follow-Up Study: 7. Results. Am J Ophthalmol. 1995;120(6):718–731. doi:10.1016/S0002-9394(14)72725-4
   PubMed Web of Science ®Google Scholar
• Rossi GC, Pasinetti GM, Scudeller L, Radaelli R, Bianchi PE. Do adherence rates and glaucomatous visual field progression correlate? Eur J Ophthalmol. 2011;21(4):410–414. doi:10.5301/EJO.2010.6112
   PubMed Web of Science ®Google Scholar
• Sleath B, Blalock S, Covert D, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Research Support, N.I.H. extramuralresearch support, Non-U.S. Gov’t. Ophthalmology. 2011;118(12):2398–2402. doi:10.1016/j.ophtha.2011.05.013
   PubMed Web of Science ®Google Scholar
• Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112(6):953–961. doi:10.1016/j.ophtha.2004.12.035
   PubMed Web of Science ®Google Scholar
• Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol. 1993;116(2):176–181. doi:10.1016/S0002-9394(14)71282-6
   PubMed Web of Science ®Google Scholar
• Kass MA, Gordon M, Morley RE, Meltzer DW, Goldberg JJ. Compliance with topical timolol treatment. Am J Ophthalmol. 1987;103(2):188–193. doi:10.1016/s0002-9394(14)74225-4
   PubMed Web of Science ®Google Scholar
• Labbe A, Terry O, Brasnu E, Van Went C, Baudouin C. Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Cornea. 2012;31(9):994–999. doi:10.1097/ICO.0b013e31823f8cb6
   PubMed Web of Science ®Google Scholar
• O’Hare F, Ghosh S, Lamoureux E, Vajpayee RB, Crowston JG. Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication. Clin Exp Ophthalmol. 2012;40(7):675–681. doi:10.1111/j.1442-9071.2012.02781.x
   PubMed Web of Science ®Google Scholar
• Valente C, Iester M, Corsi E, Rolando M. Symptoms and signs of tear film dysfunction in glaucomatous patients. J Ocul Pharmacol Ther. 2011;27(3):281–285. doi:10.1089/jop.2010.0133
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350–355. doi:10.1097/IJG.0b013e31815c5f4f
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618–621. doi:10.1097/ICO.0b013e3181c325b2
   PubMed Web of Science ®Google Scholar
• Rossi GC, Pasinetti GM, Scudeller L, Raimondi M, Lanteri S, Bianchi PE. Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients. Eur J Ophthalmol. 2013;23(3):296–302. doi:10.5301/ejo.5000220
   PubMed Web of Science ®Google Scholar
• Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with Glaucoma. Am J Ophthalmol. 2011;153(1):1–9.e2. doi:10.1016/j.ajo.2011.05.033
   PubMed Web of Science ®Google Scholar
• Bacharach J, Tatham A, Ferguson G, et al. Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). Drugs. 2021;81(17):2017–2033. doi:10.1007/s40265-021-01624-9
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Walters TR, Kolko M, et al. Phase 3, randomized, 20-month study of bimatoprost implant in open-angle Glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127(12):1627–1641. doi:10.1016/j.ophtha.2020.06.018
   PubMed Web of Science ®Google Scholar
• Craven ER, Walters T, Christie WC, et al. 24-month phase I/II clinical trial of bimatoprost sustained-release implant (Bimatoprost SR) in Glaucoma patients. Drugs. 2020;80(2):167–179. doi:10.1007/s40265-019-01248-0
   PubMed Web of Science ®Google Scholar
• Allergan, an AbbVie company. Durysta Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211911s000lbl.pdf. Accessed June 4, 2020.
   Google Scholar
• Drugs@FDA: FDA-Approved Drugs. Durysta. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211911. Accessed April 22, 2020.
   Google Scholar
• Wong MK, Bowers ME, Ventimiglia J, et al. Short-term outcomes of bimatoprost sustained-release intracameral implant in Glaucoma. J Glaucoma. 2023;32(9):738–743. doi:10.1097/IJG.0000000000002271
   PubMed Web of Science ®Google Scholar
• Bowers ME, Wong MK, Ventimiglia J, et al. Effect of bimatoprost sustained-release intracameral implant on intraocular pressure and medication burden in patients with prior glaucoma surgery. J Fr Ophtalmol. 2024;47(2):103996. doi:10.1016/j.jfo.2023.07.016
   PubMed Web of Science ®Google Scholar